CLINICAL ANDVACCINEIMMUNOLOGY, Oct. 2007, p. 1372–1376 Vol. 14, No. 10
1556-6811/07/$08.00⫹0 doi:10.1128/CVI.00202-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Monoclonal Antibody to Fungal Glucosylceramide Protects Mice
against Lethal
Cryptococcus neoformans
Infection
䌤
Marcio L. Rodrigues,
1* Li Shi,
2Eliana Barreto-Bergter,
1Leonardo Nimrichter,
1Sandra E. Farias,
4Elaine G. Rodrigues,
5Luiz R. Travassos,
5and Joshua D. Nosanchuk
2,3Instituto de Microbiologia Professor Paulo de Go´es, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, Brazil1;
Division of Infectious Diseases, Department of Medicine,2and Department of Microbiology/Immunology,3Albert Einstein College of
Medicine, Bronx, New York 10461; Departamento de Fisiologia, Instituto de Cieˆncias Ba´sicas da Sau´de, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil4; and Disciplina de Biologia Celular, Universidade
Federal de Sa˜o Paulo, Sa˜o Paulo SP 04023-062, Brazil5
Received 17 May 2007/Returned for modification 18 June 2007/Accepted 13 August 2007
Glucosylceramides (GlcCer) are involved in the regulation of Cryptococcus neoformans virulence. In the present study, we demonstrate that passive immunization with a monoclonal antibody to GlcCer significantly reduces host inflammation and prolongs the survival of mice lethally infected withC. neoformans, revealing a potential therapeutic strategy to control cryptococcosis.
Cryptococcosis, a fungal infection caused by the yeast-like pathogenCryptococcus neoformans, is an important cause of morbidity and mortality in immunosuppressed individuals, af-fecting especially the central nervous system (3, 33). Treatment failures occur and, despite high doses of antifungal drugs, the fungus is frequently not eradicated, resulting in recurrent dis-ease in individuals coinfected with human immunodeficiency virus in the absence of continued antifungal therapy (3, 8).
Passive immunization with monoclonal antibodies (MAbs) to cryptococcal antigens can protect mice against lethal C. neoformans infections (6, 11, 13, 36). Targets of protective MAbs include glucuronoxylomannan (GXM), the major cap-sular polysaccharide ofC. neoformans(6, 11, 13), the pigment melanin (36), and the cell wall polysaccharide glucan (30). Antibodies to GXM have been characterized as potential ther-apeutic agents (6) and are in clinical trials for individuals with cryptococcosis (18). In other models, passively administered MAbs have protected mice against lethal infections with His-toplasma capsulatum(26),Candida albicans(15), and Aspergil-lus fumigatus(7). The mechanisms of MAb-mediated protec-tion are complex and heterogeneous, but it appears that passively administered antibodies enhance the effectiveness of host immune cells (5, 13) or are directly antifungal (23, 35).
Glucosylceramides (GlcCer; cerebrosides; monohexosyl cer-amides) are glycosphingolipids composed of a glucose unit bound to a ceramide moiety via a glycosidic linkage. GlcCer molecules are widely distributed among pathogenic fungi and are extremely conserved structurally (1). This lipid, which is present at the fungal plasma membrane (1), cell wall (23–25, 35), and secretory vesicles (34), induces antifungal antibodies (23, 35) and regulates the virulence ofC. neoformansin animal infections (31). Based on the previously characterized ability of antibodies to GlcCer to control the growth ofC. neoformansin
vitro (35), we hypothesized that GlcCer-binding MAbs could protect mice against lethalC. neoformansinfections.
C. neoformansstrain 24067 (serotype D) was obtained from the American Type Culture Collection (Rockville, MD). C. neoformanscultures were grown in Sabouraud broth for 2 days at 30°C in a rotary shaker at 150 rpm, and cells were then washed three times in phosphate-buffered saline (PBS), pH 7.2, and collected by centrifugation at 4,000⫻g(10 min, 4°C). The MAb to GlcCer, a mouse immunoglobulin G2b (IgG2b) with the ability to enhance the antifungal properties of mac-rophages and promote direct antimicrobial activity, was pro-duced as described previously (9, 23, 30, 36). Concentrated antibody solutions were prepared from ascites of BALB/c mice injected with antibody-producing hybridoma cells. Antibodies to GlcCer were purified by Protein G affinity chromatography.
A/J mice (females, 6 to 8 weeks old; National Cancer Insti-tute, Frederick, MD) were passively immunized with the puri-fied MAb to GlcCer (100, 250, or 500g per animal, admin-istered intraperitoneally (i.p.);n⫽10 per group). This mouse strain has been used by us and many other investigators as an animal host susceptible to infection byC. neoformans(12, 22, 27, 37, 38). A/J mice are deficient in the production of the complement component C5, which is involved in the efficient control of initial steps of animal cryptococcosis (10). Twenty-four hours after immunization, mice were infected intratrache-ally (i.t.) with 1⫻106C. neoformans
cells. Mice (n⫽10 per group) injected i.p. with PBS or a commercial unrelated IgG2b prior toC. neoformansinfections were used as control groups. The survival times for the infected mice immunized with the anti-GlcCer MAb and those for PBS- or irrelevant antibody-treated mice were compared using log rank analysis (SPSS 14.0; SPSS Inc., Chicago, IL).Pvalues of less than 0.05 were considered significant. Mice were housed in the animal facility of Albert Einstein College of Medicine, and all experimental procedures adhered to protocols approved by the Animal Care and Use Committee.
As demonstrated in Fig. 1, mice given the MAb to GlcCer lived significantly longer than control mice given PBS or the irrelevant IgG2b. Although the protective effects were more
* Corresponding author. Mailing address: Instituto de Microbiologia Professor Paulo de Go´es, Universidade Federal do Rio de Janeiro, 21941-590, Brazil. Phone: 55 21 2562 6740. Fax: 55 21 25608344. E-mail: marcio @micro.ufrj.br.
䌤Published ahead of print on 22 August 2007.
pronounced when a 500-g antibody dose was used, passive immunization with 250g of purified antibody also prolonged mice survival. In other experiments, 100 g of the MAb to GlcCer was not protective (data not shown).
For CFU, cytokine, and histological analyses, mice were given 500g of a MAb (commercial IgG2b or the MAb to GlcCer) or of PBS i.p. Twenty-four hours later, mice were infected i.t. withC. neoformans(106
cells/mouse). Age-matched, noninfected mice were used to provide baseline histology and cytokine values. An-tibody or PBS-treated (n⫽5 per group) and noninfected mice (n⫽1 per group) were sacrificed on days 1 and 7 after infection. In all experimental groups, the right upper lobe of the lung was removed and placed into formalin for histology. Formalin-fixed, paraffin-embedded tissues were examined by hematoxylin-eosin staining for evaluation of histopathology and fungal distribution. The remaining tissue of each lung was homogenized in 4 ml of PBS, and aliquots were plated on brain heart infusion agar sup-plemented with penicillin-streptomycin, followed by incubation at 30°C for CFU determination. The remaining part of the suspen-sion was centrifuged, and the supernatant was stored at⫺20°C. When all samples had been collected, the supernatants from each group at each time point were pooled and cytokine/chemokine analyses were performed with a RayBio mouse cytokine antibody array II kit (RayBiotech, Inc., Norcross, GA) according to the manufacturer’s instructions. In this assay, cytokines and chemo-kines are detected by interaction with antibodies specific to each of the molecules measured. Cytokine samples were analyzed in duplicate, and the experiment was repeated with similar results. The membranes were developed radiographically, and ImageJ (http://rsb.info.nih.gov/ij/) was used to analyze the results. Statis-tical analyses and comparisons between the cytokine/chemokine values of the control group and mice given anti-GlcCer were performed using the Studentttest.
A histological analysis of lung sections revealed that admin-istration of antibody to GlcCer significantly reduced inflam-mation (Fig. 2). On day 1, although increased cellularity, es-pecially peribronchial inflammation, occurred in the lungs of mice treated with antibody to GlcCer, there was greater pres-ervation of alveolar airspace in those mice than in the controls. C. neoformansyeast cells were clearly visible in the alveolae of mice in all experimental groups. On day 7, increased numbers of yeasts were seen in the air spaces, but there was a dramatic reduction in inflammation in the lungs of mice treated with the MAb to GlcCer, whereas dense inflammation persisted in the control mice, and numerous multinucleated giant cells were present. A comparison of the total number of cells in the lungs of mice given PBS, the control MAb, or the MAb to GlcCer revealed, for the last group, a significantly smaller number of cells at both day 1 (P ⬍ 0.05) and day 7 (P ⬍ 0.01) after infection, as statistically analyzed using analysis of variance. In this early time range (1 to 7 days) of infection, the administra-tion of MAb to GlcCer did not reduce the numbers of CFU in the lungs of infected mice (data not shown).
Lung cytokine levels of mice treated with PBS, control MAb, or MAb to GlcCer were measured on days 1 and 7 after infection withC. neoformans(Fig. 3). On day 1 after infection, interleukin-4 (IL-4), IL-12, IL-12p70 and RANTES (regulated upon activation, normal T-cell expressed, and secreted pro-tein) were detected in significantly higher levels (P⬍0.05) in mice given GlcCer antibody, whereas the levels of other tested cytokines were very similar between groups. On day 7 postin-fection, mice given GlcCer antibody had significantly higher pulmonary concentrations of IL-4, IL-6, IL-12, monocyte che-moattractant protein 5 (MCP-5), and stem cell factor (P ⬍
0.05).
GlcCer in pathogenic fungi was first described two decades
ago (20). These molecules have been fully characterized at the structural level and found to be extremely conserved in a num-ber of fungal species (reviewed in reference 1). Recently, there have been several investigations of the roles of GlcCer in fungal physiology and pathogenesis. For example, GlcCer was characterized by different groups as the target of antimicrobial antibodies (9, 23, 29, 35) and plant defensins (39). In addition, the inhibition or inactivation of GlcCer synthase, the enzyme responsible for the last step in GlcCer biosynthesis, resulted in aberrant morphogenesis in different fungal models (19). InC. neoformans, a direct relationship between GlcCer expression and yeast replication was established by molecular and anti-body-based approaches (31, 35). GlcCer also regulates fungal virulence in animal models of cryptococcosis (31). Finally, this lipid is a key component of secretory vesicles transporting capsular polysaccharide (34). Given the clear relevance of GlcCer in the biology and pathogenesis ofC. neoformans, we speculated that passive immunization of mice with GlcCer-binding antibodies could have the potential to control crypto-coccosis.
In the present study, we demonstrate that a MAb to GlcCer protects mice against lethalC. neoformansinfection. Although protective antibodies to glycolipids in other microbes have been described (16), this is, to our knowledge, the first dem-onstration of protection using a MAb targeting a fungal glyco-lipid. Preliminary analyses in our laboratory indicate that the MAb to GlcCer, which binds to the cryptococcal cell wall, is
cytotoxic in vitro (25, 35) but does not opsonizeC. neoformans cells in vitro (unpublished data), possibly because of a masking of the Fc domains by capsular polysaccharides. Our in vivo data showed that CFU levels were not different between mice receiving MAb to GlcCer and controls, suggesting that direct fungal cytotoxicity by the MAb was minimal during early in-fection. Nevertheless, in comparison to controls, mice given MAb to GlcCer had dramatically reduced lung inflammatory responses. These observations suggest that the MAb-mediated protection may be a consequence of downregulation of the inflammatory response. We therefore believe that in the pres-ence of the antibodies to GlcCer, inflammatory responses are better controlled by the host, resulting in reduced damage to host tissues and more effective killing of the invading organism by host effector cells (4). Similar results were described for mice passively immunized with a protective IgG1 to GXM prior to infection withC. neoformans(14, 32). The finding of reduction of inflammation by nonopsonic antibody has also been shown with other pathogenic fungi, such asHistoplasma capsulatum(26).
The reduced inflammation in mice treated with the MAb to GlcCer corresponds to the increased lung concentrations of IL-4 on day 1 postinfection and anti-inflammatory cytokines, such as IL-4 and IL-6 (28), on day 7. It has been shown that IL-4 is necessary for MAb-mediated protection and that mice genetically deficient in IL-6 and IL-12 production have in-creased susceptibility toC. neoformansinfections (2). In
addi-FIG. 2. Histology of lungs 1 day and 7 days after i.t. infection withC. neoformans. Mice were treated 1 day prior to infection with a MAb to GlcCer or an irrelevant isotype-matched MAb. The pulmonary histology of mice receiving PBS instead of antibody prior to infection appeared similar to that for mice receiving the irrelevant antibody. Images are representative of similar sections from mice in each group. NumerousC. neoformansyeast cells were clearly visible in each section. Original magnification,⫻100. A determination of the total number of cells in each system (right panels) reveals a significant decrease in cellularity when mice were treated with anti-GlcCer before fungal infection.Pvalues originated from the statistical comparison (analysis of variance) of data obtained from mice given anti-GlcCer, and results for those given the control MAb or PBS are shown.
tion, an association between high levels of IL-6 and resistance toC. neoformansinfection has been recently described (37). Administration of MAb to GlcCer in our cryptococcal model also increased lung expression of IL-12 and IL12p70 on days 1 and 7 postinfection. IL-12 has in fact been demonstrated to have a protective effect against pulmonary infections withC. neoformansin mice (17). The elevated levels of RANTES in the lungs of mice given MAb to GlcCer were in accordance with results from a study by Uicker et al., which demonstrated that this chemokine is associated to a protective cell-mediated immunity against C. neoformans (40). On day 7, pulmonary levels of MCP-5 and stem cell factor were also elevated, a finding which may be correlated with the recruitment of monocytic cells. These results reinforce the complexity of the mechanisms through which antibodies modulate infec-tion byC. neoformans.
Cerebroside expression is associated with virulence in pul-monary cryptococcosis (31), which suggested that antibodies to GlcCer could be efficacious in modifying disease. In summary, as recently theorized by Mitchell (21), GlcCer represents a valuable target for new therapeutic agents against cryptococ-cosis. Considering the fact that fungal cerebrosides are ex-tremely conserved and expressed in virtually all pathogenic
species studied so far (1), GlcCer-binding antibodies may also be useful tools in the control of other mycoses.
J.D.N. is supported in part by NIH AI52733 and AI056070-01A2, a Wyeth Vaccine Young Investigator Research Award from the Infec-tious Disease Society of America, and the Center for AIDS Research at the Albert Einstein College of Medicine and Montefiore Medical Center (NIH AI-51519). M.L.R. is supported by grants from Conselho Nacional de Desenvolvimento Tecnolo´gico (CNPq, Brazil) and Coor-denac¸a˜o de Aperfeic¸oamento de Pessoal de Nı´vel Superior (CAPES, Brazil). L.R.T. and E.G.R. are supported by CNPq and FAPESP (Brazil). L.N. and E.B.-B. are supported by CNPq and FAPERJ.
We are indebted to Luis Silva for the preparation of ascitic fluids and antibody purification.
REFERENCES
1.Barreto-Bergter, E., M. R. Pinto, and M. L. Rodrigues.2004. Structure and biological functions of fungal cerebrosides. An. Acad. Bras. Cienc.76:76–84. 2.Beenhouwer, D. O., S. Shapiro, M. Feldmesser, A. Casadevall, and M. D. Scharff.2001. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice againstCryptococcus neoformans. Infect. Immun.
69:6445–6455.
3.Bicanic, T., and T. S. Harrison.2004. Cryptococcal meningitis. Br. Med. Bull.72:99–118.
4.Casadevall, A., and L. A. Pirofski.2003. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol.1:17–24.
5.Casadevall, A., E. Dadachova, and L. A. Pirofski.2004. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol.2:695–703.
6.Casadevall, A., W. Cleare, M. Feldmesser, A. Glatman-Freedman, D. L. Goldman, T. R. Kozel, N. Lendvai, J. Mukherjee, L. A. Pirofski, J. Rivera, A. L. Rosas, M. D. Scharff, P. Valadon, K. Westin, and Z. Zhong.1998. Characterization of a murine monoclonal antibody toCryptococcus neofor-manspolysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother.42:1437–1446.
7.Chaturvedi, A. K., A. Kavishwar, G. B. Shiva-Keshava, and P. K. Shukla.
2005. Monoclonal immunoglobulin G1 directed againstAspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis. Clin. Diagn. Lab. Immunol.12:1063–1068.
8.Chayakulkeeree, M., and J. R. Perfect.2006. Cryptococcosis. Infect. Dis. Clin. N. Am.20:507–544, v–vi.
9.da Silva, A. F. C., M. L. Rodrigues, S. E. Farias, I. C. Almeida, M. R. Pinto, and E. Barreto-Bergter.2004. Glucosylceramides inColletotrichum gloeo-sporioidesare involved in the differentiation of conidia into mycelial cells. FEBS Lett.561:137–143.
10.Dromer, F., C. Perronne, J. Barge, J. L. Vilde, and P. Yeni.1989. Role of IgG and complement component C5 in the initial course of experimental cryp-tococcosis. Clin. Exp. Immunol.78:412–417.
11.Dromer, F., J. Salamero, A. Contrepois, C. Carbon, and P. Yeni.1987. Production, characterization, and antibody specificity of a mouse monoclo-nal antibody reactive withCryptococcus neoformanscapsular polysaccharide. Infect. Immun.55:742–748.
12.Feldmesser, M., and A. Casadevall.1997. Effect of serum IgG1 to Crypto-coccus neoformansglucuronoxylomannan on murine pulmonary infection. J. Immunol.158:790–799.
13.Feldmesser, M., and A. Casadevall.1998. Mechanism of action of antibody to capsular polysaccharide inCryptococcus neoformansinfection. Front. Bio-sci.3:d136–d151.
14.Feldmesser, M., Y. Kress, and A. Casadevall.1998. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J. Infect. Dis.177:1639–1646.
15.Han, Y., M. H. Riesselman, and J. E. Cutler.2000. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun.
68:1649–1654.
16.Hustinx, W. N., K. Kraaijeveld, A. I. Hoepelman, and J. Verhoef.1997. Cross-protection by anti-core glycolipid antibodies: evidence from animal experiments. J. Antimicrob. Chemother.40:475–483.
17.Kawakami, K., M. Tohyama, Q. Xie, and A. Saito.1996. IL-12 protects mice against pulmonary and disseminated infection caused byCryptococcus neo-formans. Clin. Exp. Immunol.104:208–214.
18.Larsen, R. A., P. G. Pappas, J. Perfect, J. A. Aberg, A. Casadevall, G. A. Cloud, R. James, S. Filler, and W. E. Dismukes.2005. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal anti-body 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother.49:952–958.
19.Levery, S. B., M. Momany, R. Lindsey, M. S. Toledo, J. Shayman, M. Fuller, K. Brooks, R. L. Doong, A. H. Straus, and H. K. Takahashi.2002. Disruption of the glucosylceramide biosynthetic pathway inAspergillus nidulansand Aspergillus fumigatusby inhibitors of UDP-Glc:ceramide glucosyltransferase strongly affects spore germination, cell and hyphal growth. FEBS Lett.525:
59–64.
20.Matsubara, T., A. Hayashi, Y. Banno, T. Morita, and Y. Y. Nozawa.1987. Cerebroside of the dimorphic human pathogenCandida albicans. Chem. Phys. Lipids43:1–12.
21.Mitchell, A. P.2006. Cryptococcal virulence: beyond the usual suspects. J. Clin. Investig.116:1481–1483.
22.Mukherjee, J., M. D. Scharff, and A. Casadevall.1992. Protective murine monoclonal antibodies toCryptococcus neoformans. Infect. Immun.60:4534– 4541.
23.Nimrichter, L., E. Barreto-Bergter, R. R. Mendonca-Filho, L. F. Kneipp, M. T. Mazzi, P. Salve, S. E. Farias, R. Wait, C. S. Alviano, and M. L. Rodrigues.2004. A monoclonal antibody to glucosylceramide inhibits the
growth ofFonsecaea pedrosoiand enhances the antifungal action of mouse macrophages. Microbes Infect.6:657–665.
24.Nimrichter, L., M. D. Cerqueira, E. A. Leitao, K. Miranda, E. S. Nakayasu, S. R. Almeida, I. C. Almeida, C. S. Alviano, E. Barreto-Bergter, and M. L. Rodrigues.2005. Structure, cellular distribution, antigenicity, and biological functions ofFonsecaea pedrosoiceramide monohexosides. Infect. Immun.
73:7860–7868.
25.Nimrichter, L., M. L. Rodrigues, E. G. Rodrigues, and L. R. Travassos.2005. The multitude of targets for the immune system and drug therapy in the fungal cell wall. Microbes Infect.7:789–798.
26.Nosanchuk, J. D., J. N. Steenbergen, L. Shi, G. S. Deepe, Jr., and A. Casadevall.2003. Antibodies to a cell surface histone-like protein protect againstHistoplasma capsulatum. J. Clin. Investig.112:1164–1175. 27.Nosanchuk, J. D., P. Valadon, M. Feldmesser, and A. Casadevall.1999.
Melanization ofCryptococcus neoformansin murine infection. Mol. Cell. Biol.19:745–750.
28.Opal, S. M., and V. A. DePalo.2000. Anti-inflammatory cytokines. Chest
117:1162–1172.
29.Pinto, M. R., M. L. Rodrigues, L. R. Travassos, R. M Haido, R. Wait, and E. Barreto-Bergter.2002. Characterization of glucosylceramides in Pseudall-escheria boydiiand their involvement in fungal differentiation. Glycobiology
12:251–260.
30.Rachini, A., D. Pietrella, P. Lupo, A. Torosantucci, P. Chiani, C. Bromuro, C. Proietti, F. Bistoni, A. Cassone, and A. Vecchiarelli.2 July 2007. An anti-
glucan monoclonal antibody inhibits growth and capsule formation of Cryp-tococcus neoformansin vitro and exerts therapeutic, anti-cryptococcal activ-ity in vivo. Infect. Immun. doi:10.1128/IAI.00278-07.
31.Rittershaus, P. C., T. B. Kechichian, J. C. Allegood, A. H. Merrill, Jr., M. Hennig, C. Luberto, and M. Del Poeta.2006. Glucosylceramide synthase is an essential regulator of pathogenicity ofCryptococcus neoformans. J. Clin. Investig.116:1651–1659.
32.Rivera, J., O. Zaragoza, and A. Casadevall.2005. Antibody-mediated pro-tection againstCryptococcus neoformanspulmonary infection is dependent on B cells. Infect. Immun.73:1141–1150.
33.Rodrigues, M. L., C. S. Alviano, and L. R. Travassos.1999. Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms. Microbes Infect.1:293–301.
34.Rodrigues, M. L., L. Nimrichter, D. L. Oliveira, S. Frases, K. Miranda, O. Zaragoza, M. Alvarez, A. Nakouzi, M. Feldmesser, and A. Casadevall.2007. Vesicular polysaccharide export inCryptococcus neoformansis a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot. Cell
6:48–59.
35.Rodrigues, M. L., L. R. Travassos, K. R. Miranda, A. J. Franzen, S. Rozental, W. de Souza, C. S. Alviano, and E. Barreto-Bergter.2000. Human antibodies against a purified glucosylceramide fromCryptococcus neoformansinhibit cell budding and fungal growth. Infect. Immun.68:7049–7060.
36.Rosas, A. L., J. D. Nosanchuk, and A. Casadevall.2001. Passive immuniza-tion with melanin-binding monoclonal antibodies prolongs survival of mice with lethalCryptococcus neoformansinfection. Infect. Immun.69:3410–3412. 37.Siddiqui, A. A., R. J. Shattock, and T. S. Harrison, and T. S.2006. Role of capsule and interleukin-6 in long-term immune control ofCryptococcus neo-formansinfection by specifically activated human peripheral blood mononu-clear cells. Infect. Immun.74:5302–5310.
38.Taborda, C. P., and A. Casadevall.2001. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J. Immunol.166:2100–2107. 39.Thevissen, K., D. C. Warnecke, I. E. J. A. Franc¸ois, M. Leipelt, E. Heinz, C.
Ott, U. Za¨hringer, B. P. H. J. Thomma, K. K. A. Ferket, and B. P. A. Cammue.2004. Defensins from insects and plants interact with fungal glu-cosylceramides. J. Biol. Chem.279:3900–3905.
40.Uicker, W. C., H. A. Doyle, J. P. McCracken, M. Langlois, and K. L. Buchanan.2005. Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococ-cus neoformans. Med. Mycol.43:27–38.
